This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
5 Biotech Stocks to Watch for Potential Upside
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector.
ARQTNegative Net Change FOLDPositive Net Change PCRXPositive Net Change ANIPPositive Net Change TNGXNegative Net Change
biotechnology biotechs medical pharmaceuticals
GEHC Expands Healthcare Access Through Indonesia MoH Partnership Deal
by Zacks Equity Research
GE HealthCare partners with Indonesia's Health Ministry under SIHREN to deploy CT scanners nationwide, expanding diagnostics across public hospitals.
BSXPositive Net Change ISRGPositive Net Change MEDPNegative Net Change GEHCPositive Net Change
medical medical-devices
HOLX's Genius AI Mammography Flags Missed Breast Cancer Cases
by Zacks Equity Research
Hologic shares dip as the company unveils new study data showing its Genius AI mammography flags 32% of previously missed breast cancer cases.
ISRGPositive Net Change HOLXNegative Net Change VCYTNegative Net Change AORTPositive Net Change
genetic-testing immuno-therapy medical medical-devices
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now
by Zacks Equity Research
DXCM's strong Q3 growth, expanding CGM coverage and innovation-driven momentum position it for sustained adoption despite rising competition.
BSXPositive Net Change ISRGPositive Net Change DXCMNegative Net Change MEDPNegative Net Change
medical medical-devices
Tempus AI Turns Non-GAAP Profit on Surging Genomics and Data
by Urmimala Biswas
Tempus AI posts first positive adjusted EBITDA as genomics testing accelerates and data bookings broaden. Zacks Rank #3 (Hold) with mixed Style Scores.
TXGPositive Net Change DOCSNegative Net Change TEMNegative Net Change
artificial-intelligence consensus-outlook earnings earnings-consensus medical medical-devices
Can These 5 Relative Price Strength Stocks Lead in 2026?
by Nilanjan Choudhury
HG, KGC, ILMN, CMC and LVS are flashing relative strength heading into 2026 - could they lead the next market leg higher?
LVSNegative Net Change ILMNNegative Net Change KGCPositive Net Change CMCNegative Net Change HGPositive Net Change
basic-materials consumer-discretionary finance medical
Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?
by Sundeep Ganoria
PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.
PFENegative Net Change NVONegative Net Change LLYNegative Net Change SMMTNegative Net Change
biotechs medical pharmaceuticals vaccines
Company News for Dec 17, 2025
by Zacks Equity Research
Companies in The News Are: PFE,KHC,F,PYPL
FNegative Net Change PFENegative Net Change PYPLNegative Net Change KHCPositive Net Change
auto-tires-trucks consumer-staples medical tech-stocks
RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know
by Zacks Equity Research
Rezolute shares collapse 79% so far in December after a phase III hyperinsulinism study of its only pipeline candidate miss primary and key secondary endpoints.
ANIPPositive Net Change CRMDPositive Net Change RZLTNegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Health Insurers Now Get a Pulse: 3 Stocks to Jump in 2026
by Kaibalya Pravo Dey
Health insurers are regaining pricing control and margin visibility, putting UnitedHealth, CVS Health and Centene back in focus as managed care regains its pulse.
UNHNegative Net Change CVSNegative Net Change CNCNegative Net Change ELVNegative Net Change
insurance medical
FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug
by Zacks Equity Research
Adagene jumps 13.8% after the FDA grants Fast Track Status to muzastotug with pembrolizumab for MSS metastatic colorectal cancer.
ANIPPositive Net Change CRMDPositive Net Change CSTLPositive Net Change ADAGNegative Net Change
medical
Hologic's Genius AI Detection Shows Value by Spotting Missed Cancers
by Moumi Mondal
HOLX's Genius AI Detection flags missed breast cancers, showing promise in improving mammography accuracy and radiologist efficiency.
BDXNegative Net Change HOLXNegative Net Change GEHCPositive Net Change
medical medical-devices
How the OneStep Partnership Could Drive Growth for ZBH Stock
by Zacks Equity Research
Zimmer Biomet teams up with OneStep to integrate mobility analytics into mymobility, empowering surgeons and patients while advancing its connected care strategy.
OMCLPositive Net Change ILMNNegative Net Change ZBHPositive Net Change BTSGNegative Net Change
medical
Should You Retain Teleflex Stock in Your Portfolio Now?
by Zacks Equity Research
TFX's UroLift expansion and Barrigel traction support long-term growth, but high debt and FX headwinds keep the stock under pressure.
ILMNNegative Net Change TFXPositive Net Change PODDPositive Net Change BTSGNegative Net Change
medical
The Best Value Stocks to Buy in 2026
by Benjamin Rains
Exploring how investors can screen for the best Zacks Rank #1 (Strong Buy) value stocks to buy in 2026.
BTSGNegative Net Change
medical
Hims & Hers Scales Technology-Driven Care as Profitability Evolves
by Debanjana Dey
HIMS scales personalized care, expands globally and invests in technology as it balances growth with evolving profitability.
GDRXPositive Net Change HIMSNegative Net Change TEMNegative Net Change
medical medical-devices
BD Expands BD MAX With IVDR-Approved VIASURE Tests in Europe
by Zacks Equity Research
BDX expands its BD MAX menu in Europe with IVDR-approved respiratory and STI assays, boosting system utility and reinforcing its diagnostics growth strategy.
BDXNegative Net Change CAHPositive Net Change COOPositive Net Change BTSGNegative Net Change
immuno-therapy medical medical-devices
SNY Stock Down on Double Trouble With Multiple Sclerosis Drug
by Zacks Equity Research
Sanofi shares slide after the FDA again delays its review of its MS drug tolebrutinib, and a phase III study fails to hit its primary endpoint.
SNYPositive Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechs medical pharmaceuticals
The Longevity Shift: Healthcare REITs to Benefit From Global Aging
by Urmimala Biswas
WELL, VTR, CTRE and OHI are tapping the longevity economy as aging populations drive rising demand for senior housing, skilled nursing and long-term care real estate.
VTRPositive Net Change OHIPositive Net Change CTREPositive Net Change WELLNegative Net Change
finance healthcare medical medical-devices
KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data
by Zacks Equity Research
Kyverna Therapeutics shares jump 23% after a registrational phase II study of miv-cel meets primary and all secondary efficacy goals for treating stiff person syndrome.
ANIPPositive Net Change CRMDPositive Net Change CSTLPositive Net Change KYTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike
by Zacks Equity Research
CHMP backs EU approval of Moderna's next-generation mNexspike COVID-19 vaccine, with a final European Commission decision expected shortly.
MRNAPositive Net Change ANIPPositive Net Change CRMDPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals vaccines
Tempus AI Revenue Jumps 85% as Pricing Catalysts Line Up
by Urmimala Biswas
Tempus AI's Q3 revenue surged as oncology and hereditary testing led the way, margins improved, and pricing tailwinds and regulatory milestones took shape.
TXGPositive Net Change DOCSNegative Net Change TEMNegative Net Change
artificial-intelligence earnings-growth earnings-outlook healthcare medical medical-devices
How AbbVie's Pipeline Is Lining Up Key Product Launches
by Sundeep Ganoria
ABBV is lining up multiple late-stage launches, from Rinvoq label expansions to Parkinson???s and oncology assets nearing FDA decisions.
JNJPositive Net Change LLYNegative Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal
by Zacks Equity Research
Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.
GSKNegative Net Change GILDPositive Net Change FOLDPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
3 MedTech Stocks Poised to Gain in 2026 From the AI Boom
by Sridatri Sarkar
AI is reshaping MedTech, and Stryker, Tempus AI and GE HealthCare are emerging as key players leveraging AI across surgery, diagnostics and imaging.
SYKPositive Net Change NVDANegative Net Change GEHCPositive Net Change TEMNegative Net Change
artificial-intelligence medical medical-devices